Publications by authors named "R H J Mathijssen"
New metabolic insights into the mechanism of ifosfamide encephalopathy.
Biomed Pharmacother
December 2024
Ifosfamide causes neurotoxicity, including sometimes fatal encephalopathy, in a small number of patients. Why and how this occurs is not fully understood. It is generally believed that N-dechloroethylation of ifosfamide to 2-chloroacetaldehyde is the cause.
View Article and Find Full Text PDFPurpose: Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics.
Methods: A pooled analysis of individual patient data from four clinical trials (ALEX, J-ALEX, ALUR, and ML29453) was conducted.
Article Synopsis
- Alectinib is a treatment for ALK+ non-small cell lung cancer, but many patients experience drug-related toxicity requiring dose adjustments, potentially linked to genetic variants.
- In a study of 215 patients, 47% had severe toxicity, with females being more affected and having higher drug levels. Additionally, specific genetic variants like PPAR-α 209G>A were associated with increased toxicity.
- Identifying these genetic factors could help tailor treatments and reduce adverse effects, suggesting the need for pre-treatment genetic testing and possible dose modifications.
Introduction: Tamoxifen may adversely affect cognitive function by interfering with estrogen action in the brain. Despite growing evidence for a relationship between tamoxifen and cognitive problems, findings remain inconclusive. While some tamoxifen-related side effects seem exposure-dependent with concentrations of tamoxifen or its main metabolite, endoxifen, this has never been investigated for cognitive function.
View Article and Find Full Text PDFArticle Synopsis
- There are significant uncertainties about whether PD-1 and PD-L1 inhibitors can be used interchangeably, impacting clinical decisions and healthcare budgets.
- The paper reviews the complicated regulatory environment and market competition surrounding these inhibitors, revealing issues with clinical trial designs that make it hard to assess their interchangeability.
- To improve understanding of their interchangeability, the authors suggest more rigorous research methods, including specific types of trials and a new evaluation framework.